Dorsey & Whitney Trust CO LLC acquired a new stake in shares of Coherus BioSciences, Inc. (NASDAQ:CHRS – Free Report) in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 10,410 shares of the biotechnology company’s stock, valued at approximately $39,000. Several […]
On January 22, 2024, Sandoz announced its plans to acquire the U.S. biosimilar ranibizumab CIMERLI (ranibizumab-eqrn) from Coherus BioSciences, Inc. (“Coherus”) for an upfront cash.
BioPharma Credit PLC - London-based closed-ended investment company - Its investment manager Pharmakon Advisors LP notes Coherus Biosciences Inc on Monday saying it plans to make a partial prepayment.
Coherus BioSciences, Inc (NASDAQ:CHRS) Receives Average Rating of Moderate Buy from Brokerages theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.
Truist Financial Cuts Coherus BioSciences (NASDAQ:CHRS) Price Target to $8 00 theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.